The Company owns the following U.S. patents, which cover the IGF-MTX drug candidate and other conjugates to IGF:

U.S. Patent No. 7,811,982. Compounds and Methods For Treating Cancer
U.S. Patent No. 9,011,880. Compounds and Methods For Treating Cancer
U.S. Patent No. 8,501,906. Compounds and Methods For Treating Cancer
U.S. Patent No. 8,017,102. Toxins and Radionucleotides Coupled to Igf-1 Receptor Ligands For Treatment Of Cancer
U.S. Patent 8,920,777. Toxins and Radionucleotides Coupled to Igf-1 Receptor Ligands For Treatment Of Cancer.

The Company also has several foreign patents and several U.S. patent applications pending.

The Company also has an exclusive license to U.S. patents from Yale University and the University of Arkansas covering CPE54.